HI
AGIO icon

HBK Investments’s Agios Pharmaceuticals AGIO Stock Holding History

HBK Investments’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6,764
Closed -$553K – 994
2018
Q1 		$553K Buy
6,764
+1,409
+26% +$109K ﹤0.01% 752
2017
Q4 		$306K Buy
+5,355
New +$337K ﹤0.01% 849

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HBK Investments's AGIO Position: Q2 2018 in Review

HBK Investments sold out of Agios Pharmaceuticals (AGIO) in Q2 2018, closing a stake of 6,764 shares — an estimated $553K sold.

HBK Investments first reported a position in AGIO in Q4 2017 and held it in 2 quarters. The position peaked at $553K in Q1 2018. 217 funds tracked by Wall St. Rank hold AGIO as of Q2 2018.

  • HBK Investments reported no remaining Agios Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • HBK Investments sold 6,764 Agios Pharmaceuticals shares in Q2 2018, an estimated $553K.
  • HBK Investments first reported a position in Agios Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • HBK Investments's Agios Pharmaceuticals position peaked at $553K in Q1 2018.
  • 217 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2018.

Based on HBK Investments's 13F filing for Q2 2018, filed 14 Aug 2018.